Oh, hey Barbie. There's a new girl on the block and she is not like any other doll on the market. This Barbie wears an adorable blue polka dot top, a ruffled minikirt, and an insulin pump.She is Mattel's first doll with type 1 diabetes. The doll was made in collaboration with a diabetes research organization to make sure all the accessories are accurate. ...

GALWAY, Ireland, July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to beco ...

Core Insights - Medtronic plc has appointed Dr. Joon Lee, CEO of Emory Healthcare, as an independent director on its Board, effective June 18, 2025 [1] - Dr. Lee will contribute to the Science and Technology Committee and Compensation and Talent Committee [1] Company Overview - Medtronic is a global leader in healthcare technology, headquartered in Galway, Ireland, with a mission to alleviate pain, restore health, and extend life [6] - The company employs over 95,000 people across more than 150 countries and addresses 70 health conditions with its technologies [6] Dr. Joon Lee's Background - Dr. Lee has over 25 years of experience at the University of Pittsburgh Medical Center (UPMC), where he held significant roles including Executive Vice President and President of Physician Services [3] - He has a strong background in cardiology, having served as Chief of the Division of Cardiology and founding executive director of the UPMC Heart and Vascular Institute [4] - Dr. Lee's educational credentials include a BA from Dartmouth College and an MD from Duke University, along with extensive training in cardiology at Massachusetts General Hospital [5] Financial and Operational Insights - Emory Healthcare, under Dr. Lee's leadership, generates $7.7 billion in annual revenue and operates 12 hospitals with over 29,000 employees [2] - Dr. Lee also served as Chief Medical Officer of UPMC Insurance Services, which is a $13 billion health insurance division [4] Strategic Vision - Dr. Lee is recognized for his commitment to leveraging data and technology to enhance patient and provider experiences, aligning with Medtronic's mission [2]

Key Takeaways TNDM launched early U.S. access for t:slim X2 pump compatible with Abbott's FreeStyle Libre 3 Plus sensor. Abbott's Libre 3 Plus sends glucose data every minute to TNDM's t:slim mobile app. TNDM plans to integrate Abbott's future sensors for broader diabetes management solutions.Tandem Diabetes Care, Inc.’s (TNDM) t:slim X2 insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now compatible with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) senso ...

Deal Overview - Medtronic plc announced its intent to spin off its Diabetes business into a standalone entity, referred to as the New Diabetes Company, to streamline its portfolio and focus on high-margin growth areas [2][3] - The separation is expected to be completed within 18 months, primarily through a capital markets transaction, with a preferred path of an initial public offering (IPO) [3] Company Focus Post Spin-Off - Post spin-off, Medtronic will concentrate on its core franchises in cardiovascular, neuroscience, surgical, and medical-surgical technologies, which together account for over 90% of its total revenues [3][6] - The company aims to accelerate growth through innovation in areas such as pulsed field ablation, renal denervation, soft tissue robotics, and neuromodulation [3] Financial Implications - The transaction is anticipated to be accretive to Medtronic's gross and operating margins, and earnings per share, while enabling the NewCo to pursue focused innovation and growth strategies tailored to the diabetes market [4] - Medtronic expects its dividend per share to remain unchanged pre- and post-transaction, with no change to its dividend policy [4] Diabetes Segment Performance - The Diabetes segment contributed approximately $2.5 billion in FY25, about 8% of Medtronic's total revenue of $32.4 billion, but has underperformed with a revenue CAGR of just ~1.4% compared to Medtronic's overall ~2.9% CAGR [7][6] - The segment's operating margin has declined significantly from 30.9% in FY19 to 15.8% in FY25, indicating challenges in profitability [7] Market Challenges - The Diabetes segment has faced multiple headwinds, including FDA regulatory setbacks and increasing competition from agile players like Dexcom and Abbott [8] - Despite a recent rebound with a growth of ~10.7% YoY in FY25, the improvement is insufficient to offset structural challenges [9] Strategic Goals for New Diabetes Company - The New Diabetes Company will focus on creating a complete ecosystem for intensive insulin management, including insulin pumps, continuous glucose monitoring, and digital health solutions [3][33] - The separation is expected to unlock value for Medtronic and its shareholders, creating a shareholder base more aligned with the financial profile of the New Diabetes Company [12] Company Overview - Medtronic plc is a global healthcare technology leader, operating in over 150 countries and focusing on improving patient outcomes through innovation in various medical technologies [13][32] - The company operates through four primary segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes, addressing a wide range of health conditions [32]

Embecta (EMBC) 2025 Conference June 05, 2025 04:55 PM ET Speaker0 All right. Good afternoon, everyone. My name is Mike Sarcone. I'm an analyst on the US medical supplies and devices team here. And this is the last session for Jefferies twenty twenty five New York Healthcare Conference and this is a fireside chat with MBECTA. And from the company we've got Jake Elgouy, CFO and we're also joined here by Pravesh Kandawal who heads the IR function. So gentlemen, thank you both for being with us today. Speaker1 ...

Core Viewpoint - Medtronic plc will participate in Bernstein's 41st Strategic Decisions Conference on May 29, 2025, where CEO Geoff Martha will present and answer questions alongside CFO Thierry Piéton [1][2]. Company Overview - Medtronic is a leading global healthcare technology company headquartered in Galway, Ireland, with a mission to alleviate pain, restore health, and extend life [4]. - The company employs over 95,000 people across more than 150 countries and addresses 70 health conditions through various technologies and therapies, including cardiac devices, surgical robotics, and patient monitoring systems [4]. - Medtronic aims to deliver innovative technologies that transform lives, impacting two people every second [4]. Event Details - The presentation by CEO Geoff Martha will begin at 11:00 a.m. EDT on May 29, 2025, followed by a Q&A session with CFO Thierry Piéton [2]. - A live webcast of the event will be available on Medtronic's investor relations website, with an archive accessible later the same day [3].

Embecta (EMBC) 2025 Investor Day May 22, 2025 09:00 AM ET Speaker0 Good morning, everyone, and welcome to Ambecta's first ever analyst and investor day. My name is Pravesh Khandilwal, and I'm the vice president of investor relations. The slides that accompanies today's event and webcast replay details are available on the investor relations section of our website at www.mbecta.com. Before we begin, I would like to remind you that some of the matters discussed in the event will contain forward looking statem ...

Core Insights - Tandem Diabetes Care, Inc. is focused on innovative solutions for diabetes management and is expanding its international presence, which is expected to drive growth despite macroeconomic challenges and competitive pressures [1][2][10]. Group 1: Company Performance - Tandem Diabetes has experienced a significant stock decline of 56.4% over the past year, compared to a 12.1% decline in the industry, while the S&P 500 has risen by 12.5% during the same period [2]. - The company has a market capitalization of $1.57 billion and projects an earnings growth rate of 44.5% for 2026, surpassing the industry's growth rate of 20.8% [2]. - In the last four quarters, Tandem Diabetes has exceeded earnings estimates twice and missed them twice [2]. Group 2: Product Innovation - The t:slim X2 insulin pump software, launched in 2023, is now compatible with Dexcom G7 and G6 Continuous Glucose Monitoring systems, and has received approval for sale in Canada [4]. - The t:slim X2 is the first pump in the U.S. integrated with Abbott's FreeStyle Libre 2 Plus sensor, enhancing its competitive edge [4]. - The new Tandem Mobi device is under development, featuring a tubeless patch option for insulin delivery, which aims to expand wearability options [5]. Group 3: International Expansion - Sales outside the U.S. increased by 35.4% year-over-year in Q1 2025, with approximately 11,000 pumps shipped to 25 international markets [6]. - The company is enhancing its international strategy by appointing new leadership with global diabetes experience and aligning its technology offerings with its U.S. portfolio [6]. Group 4: Market Trends - The diabetes market is expected to grow due to an aging population, unhealthy lifestyles, and increased healthcare spending, with over 5 million people living with type 1 diabetes in the U.S. [7]. - The company aims to expand the adoption of insulin pumps among type 1 and type 2 diabetes patients, with recent FDA clearance for its Control IQ+ technology for type 2 diabetes patients [9]. Group 5: Challenges - Ongoing macroeconomic uncertainties may hinder the company's ability to predict product demand, potentially increasing operational costs [10]. - The competitive landscape includes numerous players, making it challenging for Tandem Diabetes to implement pricing strategies and maintain market share [11]. Group 6: Financial Projections - The Zacks Consensus Estimate for Tandem Diabetes' 2025 loss per share is projected at $1.37, reflecting a year-over-year improvement of 28.3% [12]. - The estimated revenue for 2025 is $1.01 billion, indicating a 10.5% increase from the previous year [12].

Core Insights - Medtronic plc will report its financial results for the fourth quarter and full fiscal year 2025 on May 21, 2025, with a news release at approximately 5:45 a.m. CDT [1] - A video webcast will be held at 7:00 a.m. CDT on the same day to discuss the financial results, with a replay and transcript available within 24 hours [2] - Looking ahead, Medtronic plans to report its quarterly results for fiscal year 2026 on August 19, November 18, February 17, and May 20 of the respective years [3] Company Overview - Medtronic, headquartered in Galway, Ireland, is a leading global healthcare technology company focused on addressing significant health challenges through innovative solutions [4] - The company employs over 95,000 people across more than 150 countries and offers technologies that treat 70 health conditions, including cardiac devices, surgical robotics, and patient monitoring systems [4] - Medtronic's mission is to alleviate pain, restore health, and extend life, emphasizing a commitment to delivering transformative healthcare solutions [4]